Your browser doesn't support javascript.
loading
Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.
González García, Andrés; Fabregate, Martin; Manzano, Luis; Guillén Del Castillo, Alfredo; Rubio Rivas, Manuel; Argibay, Ana; Marín Ballvé, Adela; Rodríguez Pintó, Ignasi; Pla Salas, Xavier; Marí-Alfonso, Begoña; Callejas Moraga, Eduardo; Colunga Argüelles, Dolores; Sáez Comet, Luis; González-Echávarri, Cristina; Ortego-Centeno, Norberto; Vargas Hitos, José Antonio; Todolí Parra, José Antonio; Trapiella Martínez, Luis; Herranz Marín, María Teresa; Freire, Mayka; Chamorro, Antonio-J; Perales Fraile, Isabel; Madroñero Vuelta, Ana Belén; Sánchez Trigo, Sabela; Tolosa Vilella, Carles; Fonollosa Pla, Vicent; Simeón Aznar, Carmen Pilar.
Afiliación
  • González García A; Systemic Autoimmune Diseases Unit, Department of Internal Medicine. Hospital Universitario Ramón y Cajal, Universidad de Alcalá (UAH), IRYCIS, Carretera Colmenar Km 9.1, Madrid 28034, Spain; Faculty of Medicine and Health Sciences, Universidad de Alcalá (UAH). Alcalá de Henares, Madrid, Spain. Elect
  • Fabregate M; Department of Internal Medicine, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  • Manzano L; Department of Internal Medicine, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Faculty of Medicine and Health Sciences, Universidad de Alcalá (UAH). Alcalá de Henares, Madrid, Spain.
  • Guillén Del Castillo A; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Rubio Rivas M; Unit of Autoimmune Diseases, Department of Internal Medicine, IDIBELL. L'Hospitalet de Llobregat, Hospital Universitario de Bellvitge, Barcelona, Spain.
  • Argibay A; Department of Internal Medicine Complejo, Unit of Systemic Autoimmune Diseases and Thrombosis, Hospitalario Universitario de Vigo. Vigo, Pontevedra, Spain.
  • Marín Ballvé A; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Zaragoza, Spain.
  • Rodríguez Pintó I; Department of Internal Medicine, Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain.
  • Pla Salas X; Department of Internal Medicine, Unit of Systemic Autoimmune Diseases, Consorci Hospitalari de Vic. Vic, Barcelona, Spain.
  • Marí-Alfonso B; Department of Internal Medicine, Parc Taulí, Hospital Universitario. Sabadell, Barcelona, Spain.
  • Callejas Moraga E; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
  • Colunga Argüelles D; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
  • Sáez Comet L; Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • González-Echávarri C; Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.
  • Ortego-Centeno N; Department of Internal Medicine, Inst Invest Biosanitaria Ibs Granada, Unit of Systemic Autoimmune Diseases. Department of Medicine, Facultad de Medicina, Hospital Universitario San Cecilio, Granada, Spain.
  • Vargas Hitos JA; Department of Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Todolí Parra JA; Department of Internal Medicine, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Trapiella Martínez L; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
  • Herranz Marín MT; Department of Internal Medicine, Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain.
  • Freire M; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
  • Chamorro AJ; Department of Internal Medicine, Hospital Clínico Universitario de Salamanca-IBSAL, Salamanca, Spain.
  • Perales Fraile I; Department of Internal Medicine, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.
  • Madroñero Vuelta AB; Department of Internal Medicine, Hospital General San Jorge, Huesca, Spain.
  • Sánchez Trigo S; Department of Internal Medicine Complejo, Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain.
  • Tolosa Vilella C; Department of Internal Medicine, Parc Taulí, Hospital Universitario. Sabadell, Barcelona, Spain.
  • Fonollosa Pla V; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Simeón Aznar CP; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Semin Arthritis Rheum ; 55: 152033, 2022 08.
Article en En | MEDLINE | ID: mdl-35691226
OBJECTIVES: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc. METHODS: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival. RESULTS: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death. CONCLUSIONS: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Telangiectasia / Disfunción Ventricular Izquierda / Esclerodermia Difusa Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Semin Arthritis Rheum Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Telangiectasia / Disfunción Ventricular Izquierda / Esclerodermia Difusa Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Semin Arthritis Rheum Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos